Oostenbrink Jan B, Al Maiwenn J, Rutten-van Mölken Maureen P M H
Institute for Medical Technology Assessment, Erasmus Medical Centre Rotterdam, 3000 DR Rotterdam, PO Box 1738, Rotterdam, The Netherlands.
Pharmacoeconomics. 2003;21(15):1103-12. doi: 10.2165/00019053-200321150-00004.
Missing data resulting from premature study withdrawal are a common problem in the analysis of longitudinal data in clinical trials. To date, this subject has received little attention in the context of economic evaluations and with regard to the analysis of cost data.
To (i) demonstrate the impact of patients who drop out during the study on the outcomes of an economic evaluation, and (ii) to compare the mean and variation in costs after applying five different methods to deal with incomplete data: multiple imputation, complete cases analysis, linear extrapolation, predicted mean and hot decking.
The study was performed using cost data collected in two randomised clinical trials comparing patients with chronic obstructive pulmonary disease receiving either tiotropium bromide or ipratropium bromide. The overall dropout rate was 17%, with the daily costs of the dropouts approximately 4 times higher than the costs of the completers.
Multiple imputation is a principled method that deals with missing observations by replacing each missing observation with a set of multiple plausible values. The variance between the resulting multiple datasets is combined with the variance between the datasets to take account of the extra uncertainty that results from missing data. The outcomes after multiple imputation were compared with the results of four naive methods to deal with missing observations: complete cases analysis, linear extrapolation, predicted mean and hot decking. All costs were expressed in 2001 euros.
In the tiotropium bromide group, mean (standard error) costs varied from Euro 955 (137) after complete cases analysis to Euro 1298 (198) after linear extrapolation. The corresponding estimates in the ipratropium bromide group were Euro 970 (125) and Euro 1561 (244), respectively. The difference in costs between treatment groups varied from -Euro 15 (95% CI: -379 to 349) after complete cases analysis to -Euro 402 (95% CI: -883 to 79) after predicted mean, in favour of the tiotropium bromide group. The difference in costs according to the other methods varied from -Euro 263 (95% CI: -878 to 353) after linear extrapolation to -Euro 265 (95% CI: -709 to 180) after multiple imputation to -Euro 359 (95% CI: -771 to 54) after hot decking.
This study showed that the method of dealing with the data of the dropouts had a large impact on the outcomes of an economic evaluation. Information about the rate of patient withdrawal and the way data of dropouts are treated is of vital importance in assessing the results of economic evaluations and should always be reported. Multiple imputation is a principled method that can be used to deal with the data of these patients.
在临床试验纵向数据分析中,因研究提前终止导致的数据缺失是一个常见问题。迄今为止,在经济评估背景下以及成本数据分析方面,这一主题几乎未受到关注。
(i)证明研究期间退出的患者对经济评估结果的影响,以及(ii)比较应用五种不同方法处理不完整数据后成本的均值和变异情况:多重填补法、完全病例分析法、线性外推法、预测均值法和热卡填补法。
本研究使用了两项随机临床试验收集的成本数据,这两项试验比较了接受噻托溴铵或异丙托溴铵治疗的慢性阻塞性肺疾病患者。总体退出率为17%,退出患者的每日成本约为完成研究患者成本的4倍。
多重填补法是一种有原则的方法,通过用一组多个合理值替换每个缺失观测值来处理缺失观测值。由此产生的多个数据集之间的方差与数据集之间的方差相结合,以考虑缺失数据导致的额外不确定性。将多重填补后的结果与四种处理缺失观测值的简单方法的结果进行比较:完全病例分析法、线性外推法、预测均值法和热卡填补法。所有成本均以2001年欧元表示。
在噻托溴铵组中,完全病例分析后的平均(标准误)成本为955欧元(137),线性外推后为1298欧元(198)。异丙托溴铵组的相应估计值分别为970欧元(125)和1561欧元(244)。治疗组之间的成本差异从完全病例分析后的-15欧元(95%CI:-379至349)到预测均值后的-402欧元(95%CI:-883至79)不等,支持噻托溴铵组。根据其他方法,成本差异从线性外推后的-263欧元(95%CI:-878至353)到多重填补后的-265欧元(95%CI:-709至180)再到热卡填补后的-359欧元(95%CI:-771至54)不等。
本研究表明,处理退出患者数据的方法对经济评估结果有很大影响。关于患者退出率以及退出患者数据处理方式的信息在评估经济评估结果时至关重要,应始终予以报告。多重填补法是一种可用于处理这些患者数据的有原则的方法。